Roche Has Hopes Of Accelerating Hematology Programs With Surrogate Endpoint
Executive Summary
Roche execs made surrogate endpoints the theme of the company’s recent late-stage pipeline review, highlighting in particular the possible use of minimal residual disease as a surrogate endpoint in the clinical trials for its hematologic agents.